Bacterial skin infections result in significant morbidity and have contributed to enhanced health-care resource utilization. The problem is heightened by emerging antimicrobial resistance. Multiple novel agents active against resistant pathogens that cause skin infections-including dalbavancin, tedizolid phosphate, oritavancin, and delafloxacin-have been approved over the past 5 years. Common features of these agents include gram-positive activity and favorable safety. Of these agents, delafloxacin is unique in being active against both gram-positive and gram-negative pathogens that cause skin infections, including those resistant to other antimicrobial agents. It is, therefore, an effective option for the treatment of skin infections.
Bacterial skin and skin structure infections-also referred to as skin and soft tissue infections, skin and skin structure infections (SSSI), and (since 2013) acute bacterial skin and skin structure infections (ABSSSI)-impose a significant clinical and economic burden, estimated on the basis of health-care resource utilization. Rates of visits to health-care facilities in the United States for treatment of ABSSSIs increased significantly between 1997 and 2005, from 32.1 to 48.1 visits per 1000 people in the population, representing an increase of 50% and translating into 14.2 million visits in 2005 [1] . Another study reported significant increases in ABSSSI-related hospital admissions, from 1.6% of all hospital admissions in 2005 to 2.0% in 2011 [2] . The current epidemiology and burden of skin infections is discussed in greater detail by Kaye et al in this supplement [X] .
The predominant bacterial species associated with skin infections is Staphylococcus aureus, with other gram-positive (eg, Streptococcus pyogenes, other Beta hemolytic streptococci, and enterococci) as well as gram-negative species (eg, Pseudomonas aeruginosa and Escherichia coli) also implicated as causative organisms [3] [4] [5] .
Of concern is the emergence of resistance to antimicrobial agents over time, particularly among isolates of S. aureus, which have shown increasing frequencies of resistance to methicillin (methicillin-resistant S. aureus [MRSA] ) and other antimicrobial agents globally [5] [6] [7] . Moreover, MRSA isolates causing skin infections are often also resistant to macrolides and fluoroquinolones [8, 9] . Increased resistance translates into higher morbidity and costs [10, 11] . An additional concern is the emergence of vancomycin-resistant enterococcus (VRE), which can cause wound infections [12] . These concerns prompted efforts to develop new antimicrobial agents that are effective against resistant pathogens, with multiple agents having been approved in the United States within the past decade and additional agents under development for the treatment of ABSSSI [13, 14] . Agents approved in the last 10 years include telavancin, ceftaroline, dalbavancin, tedizolid phosphate, oritavancin, and delafloxacin.
This review provides clinicians with a comparative overview of the antimicrobial activity of antibiotics approved for the treatment of ABSSSI in adults in the United States and Europe over the past 5 years (dalbavancin, tedizolid phosphate, oritavancin, and delafloxacin). Included are studies evaluating the in vitro activity of these agents against both gram-positive and gram-negative pathogens causing ABSSSIs. The antimicrobial activity of these agents is discussed below, with data on activity against gram-positive and gram-negative pathogens being summarized in Tables 1 and 2 , respectively.
Dalbavancin
Dalbavancin, a second-generation lipoglycopeptide, was approved in the United States and Europe for the treatment of ABSSSIs in adults on the basis of non-inferiority against vancomycin and linezolid [22] . Its activity against gram-positive clinical isolates that cause ABSSSIs has been extensively documented [15, [23] [24] [25] (Tables 1 and 2 ) [18, 19] . Together, these studies evaluating activity against ABSSSI isolates, collected over a 3-year period from 2 geographic regions, highlight its continued activity over time.
DISCUSSION AND CONCLUSIONS
Collectively, the reviewed studies highlight the comparative in vitro activity of agents approved over the past 5 years against bacterial pathogens that cause skin infections. An important characteristic of these antibiotics is their broad-spectrum activity against gram-positive pathogens implicated in skin infections, including resistant organisms [34] [35] [36] [37] [38] . Moreover, delafloxacin is also active against gram-negative pathogens [17] [18] [19] [20] . Notably, delafloxacin has been shown to be significantly more active against S. aureus at a low pH, as compared with moxifloxacin, with this higher activity being attributed to its higher intracellular accumulation at a lower pH, which, in turn, is a function of it being predominantly uncharged at the low pH [39] (see also the review by Tulkens and colleagues in this issue [X] ). The broad spectrum of activity of delafloxacin augurs well for addressing an important, unmet need: namely, the emergence of resistance and a consequent reduction in efficacy.
The trend of resistance in S. aureus, particularly MRSA, has been tracked globally by the SENTRY Antimicrobial Surveillance Program [40] . Over the last 20 years (1997-2016), the rise of MRSA reached its peak 10 years ago and has been decreasing since then in all regions. In addition, the susceptibility of some older agents has increased, and may be associated with the emergence of epidemic clones (eg, USA 300) with fewer resistance determinants. Several of the newer agents discussed in this review have maintained excellent in vitro activity against S. aureus. The trend of increasing susceptibility was not the same for enterococci, with the prevalence of VRE increasing in all regions over the same period [41] . However, newer agents have maintained their excellent in vitro activities against VRE.
The choice of antimicrobial agents for the treatment of skin infections depends largely on the agent's spectrum of activity, including against resistant pathogens. Delafloxacin, with its activity against both gram-positive (including MRSA) and gram-negative pathogens and its heightened activity in the acidic environments characteristic of skin abscesses, presents an effective therapeutic option for the treatment of skin infections.
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